1. Clinical Overview of IGF-1 LR3

Molecule: Recombinant IGF-1 modified with Arginine substitution at position 3 and 13-amino-acid N-terminal extension → 10× reduced IGFBP affinity, ~20–30 hr half-life (native IGF-1 = 8–16 min), significantly increased bioavailability.

Classification: Potent anabolic/lean-mass peptide · Muscle-repair peptide · Anti-catabolic metabolic peptide · Cell-growth mediator · GH-axis downstream effector

Key Principle: IGF-1 LR3 is more targeted and efficient than simply elevating GH because it bypasses pituitary regulation and acts directly at the tissue level.

2. Mechanisms of Action

2.1 IGF-1 Receptor (IGF-1R) Activation

Triggers PI3K/Akt and MAPK pathways → muscle protein synthesis, satellite cell proliferation. Result: Faster repair, increased hypertrophy, improved recovery.

2.2 Satellite Cell Activation

Expands satellite cell pool, accelerates differentiation into new muscle fibers, enhances muscle memory, supports long-term hypertrophy. This mechanism is unique among peptides.

2.3 Anti-Catabolic Action

Reduces muscle breakdown, post-exercise protein degradation, and catabolic glucocorticoid impacts. Useful for aging adults, post-illness recovery, chronic inflammatory patients, and body recomposition.

2.4 Fat Oxidation & Metabolic Enhancement

Improves mitochondrial function, nutrient partitioning (more to muscle, less to fat), insulin sensitivity (dose-dependent), and exercise endurance.

2.5 Tissue Repair Beyond Muscle

Influences tendon/ligament cell proliferation, neural regeneration, bone turnover, and cartilage protection.

3. Evidence-Supported Clinical Domains

3.1 Muscle Growth & Strength

Lean mass preservation, post-surgical recovery, sarcopenia support, accelerated hypertrophy.

3.2 Injury Recovery & Rehab

Tendon/ligament repair, muscle tears, cartilage regeneration, nerve healing. Strong synergy with BPC-157 and TB-500.

3.3 Sarcopenia

IGF-1 decline with age contributes to weakness, frailty, fall risk. IGF-1 LR3 restores anabolic balance.

3.4 Metabolic Dysfunction & Fat Loss

Nutrient partitioning, increased basal metabolic rate, enhanced glucose utilization.

3.5 Cognitive & Neural Repair

Stimulates neurogenesis, synaptic plasticity, myelin protection. Used adjunctively in TBI recovery.

4. Administration Routes & Clinical Protocols

4.1 Subcutaneous (Most Common)

Base (Regeneration/Anti-Aging): 20–40 mcg SC daily · 4–6 weeks
Performance/Recomposition: 40–80 mcg SC daily · Fasted AM or pre-workout
Advanced (Research): 80–120 mcg SC/day (1–2 doses) · Specialized contexts only

4.2 Intramuscular (IM) Protocols

Localized IM: 20–50 mcg into target muscle · Post-training or during rehab · 1×/day, ≤5 days/week
Useful for quad/hamstring tears, rotator-cuff injuries, pectoral/calf strain, post-op wasting.

4.3 Cycling

Standard: 4–8 weeks · Advanced: up to 12 weeks with breaks · Minimum break: 4 weeks (prevent receptor downregulation).

4.4 Timing

Pre-workout for hypertrophy · Post-injury for repair · Fasted AM for fat-loss. Avoid carbs 1 hour post-injection to maximize nutrient partitioning.

5. Combination Therapy (Peptide Protocol Portal Synergy)

5.1 IGF-1 LR3 + CJC-1295 (No DAC) + Ipamorelin

Triple-action hormonal synergy for muscle building, fat loss, and anti-aging.

5.2 IGF-1 LR3 + BPC-157 + TB-500

Ultimate injury-recovery regiment. Used extensively in post-surgical and sports medicine.

5.3 IGF-1 LR3 + MOTS-c / SS-31

Metabolic + mitochondrial optimization. Enhances endurance and recovery.

5.4 IGF-1 LR3 + 1-Amino-1MQ + SLU-PP-332

Metabolic transformation programs.

5.5 IGF-1 LR3 + NAD+

Cellular energy + anabolic signaling synergy.

6. Clinical Decision Trees

Decision Tree 1 — Should IGF-1 LR3 Be Used?

Muscle repair or injury recovery needed? → YES

Patient experiencing sarcopenia? → YES

Performance or body recomposition goal? → YES

Diabetic or insulin-resistant? → Use caution; adjust dosing

Desires GH benefits without GH itself? → IGF-1 LR3 indicated

Decision Tree 2 — Route & Dose Selection

Goal: Regeneration? → 20–40 mcg SC QD

Goal: Muscle growth / recomp? → 40–80 mcg SC QD

Goal: Local injury repair? → 20–50 mcg IM in target muscle

Goal: Advanced performance? → 80–120 mcg QD (specialized only)

7. Integrated Treatment Archetypes

Archetype A — Injury Repair & Orthopedic Recovery

Systemic: IGF-1 LR3 daily + BPC-157 + TB-500 + Collagen/vitamin C

Outcome: Regeneration of muscle, tendon, ligament, and bone.

Archetype B — Body Recomposition & Lean-Mass Enhancement

Systemic: IGF-1 LR3 40–80 mcg QD + CJC-1295 + Ipamorelin + SLU-PP-332 + 1-Amino-1MQ

Outcome: Increased lean mass, decreased fat.

Archetype C — Sarcopenia / Aging Protocol

Systemic: IGF-1 LR3 20–30 mcg QD + MOTS-c weekly + NAD+ + resistance exercise

Outcome: Improved strength, mobility, vitality.

Archetype D — Neurorepair / Cognitive Support

Systemic: IGF-1 LR3 20 mcg QD + SS-31 + NAD+ + DSIP (sleep architecture)

Outcome: Adjunctive neuroregeneration support.

8. Expected Clinical Timeline

Week 1–2: Increased recovery, mild hypertrophy
Week 3–6: Body composition changes, performance improvement
Week 6–12: Peak lean mass and metabolic enhancement
Post-cycle: Improvements maintain with training

9. Contraindications & Precautions

Absolute

Active cancer (particularly IGF-sensitive tumors)
Pregnancy
Breastfeeding

Relative

Diabetes or insulin resistance (monitor glucose)
History of organomegaly
Uncontrolled hypertension

10. Adverse Effects

Possible: Hypoglycemia, joint pain, water retention (rare), headache, temporary fatigue.

Serious but rare: Visceral organ enlargement (high-dose misuse).

11. Monitoring

Fasting glucose
HbA1C (long cycles)
IGF-1 levels
Body composition
Muscle recovery markers
Liver enzymes (rarely impacted but prudent)

Legal Disclaimer

The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

IGF-1 LR3, and other peptides referenced herein are not FDA-approved drugs. Their clinical use may constitute off-label or investigational use.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References — IGF-1 LR3 Clinical Reference Guide

Foundational IGF-1 Biology & Muscle Physiology

1. Le Roith, D., et al. The somatomedin hypothesis: 2001 update. Endocrine Reviews, 22(1), 53–74 (2001).

2. Yakar, S., et al. IGF-1 effects on muscle growth and whole-body metabolism. PNAS, 98(18), 10403–10408 (2001).

3. Clemmons, D. R. Role of IGF-1 in skeletal muscle physiology. J Applied Physiology, 93(1), 25–31 (2002).

4. Musarò, A., et al. Local IGF-1 isoforms and muscle repair. Nature, 400, 581–585 (1999).

5. Philippou, A., et al. IGF-1 isoforms and muscle regeneration. Growth Hormone & IGF Research, 17(3), 177–188 (2007).

6. Shavlakadze, T., et al. IGF-1 improves muscle repair after nerve or mechanical injury. J Physiology, 590(11), 2845–2860 (2012).

7. Florini, J. R., et al. IGF-1 stimulates muscle cell differentiation and hypertrophy. Am J Physiology, 255, C701–C708 (1988).

8. Carson, J. A., & Wei, L. Integrating IGF-1 and resistance training for optimal muscle remodeling. Exercise & Sport Sciences Reviews, 8(1), 50–58 (2000).

9. Semenova, E., et al. IGF-1 expression is associated with anabolic response and athletic performance. Human Physiology, 44(2), 124–131 (2018).

10. Daughaday, W. H., & Rotwein, P. IGF-1 structure, function, and receptor signaling. Annual Review of Physiology, 51, 701–724 (1989).

Pharmacokinetics, Receptor Interactions & LR3 Modifications

11. Francis, G. L., et al. Enhanced potency of LR3 IGF-1 through reduced IGFBP binding. Biochemical Journal, 291(1), 53–59 (1993).

12. Hodgkinson, S. C., et al. Arg3 IGF-1 analogues: Binding dynamics and extended half-life. J Endocrinology, 158(1), 77–85 (1998).

13. Bach, L. A. IGFBPs and IGF bioavailability: Relevance to LR3 IGF-1. Molecular & Cellular Endocrinology, 195(1–2), 9–18 (2002).

Metabolic & Insulin Sensitivity

14. Clemmons, D. R. Metabolic actions of IGF-1 and interactions with insulin signaling. Endocrine Reviews, 34(1), 1–19 (2013).

15. Frystyk, J. Free IGF-1 and metabolic health. Growth Hormone & IGF Research, 14(5), 337–375 (2005).

16. Liu, J. L., et al. IGF-1 improves insulin sensitivity and reverses metabolic dysfunction. Endocrinology, 143(2), 474–481 (2002).

Neuroprotection & Cognitive Effects

17. Aleman, A., et al. IGF-1 and cognitive function in aging. Neurology, 59(3), 371–373 (2002).

18. Sonntag, W. E., et al. IGF-1 as a neuroprotective hormone. Trends in Endocrinology & Metabolism, 16(4), 177–183 (2005).

19. Carro, E., & Torres-Alemán, I. IGF-1 in Alzheimer's disease and neuroinflammation. J Endocrinology, 201(1), 1–12 (2009).

20. Trejo, J. L., et al. IGF-1 mediates exercise-induced neurogenesis. Nature Neuroscience, 4(3), 229–234 (2001).

Tendon, Ligament, Bone & Connective Tissue Repair

21. Abrahamsson, S. O. IGF-1 and tendon healing. Acta Orthopaedica Scandinavica, 68(6), 607–612 (1997).

22. Wang, J. H.-C., & Iosifidis, M. IGF-1 enhances tendon fibroblast proliferation. J Orthopaedic Research, 19(5), 865–872 (2001).

23. Firth, S. M., & Baxter, R. C. IGF-1 actions in bone metabolism. Frontiers in Endocrinology, 30(2), 248–261 (2002).

Aging, Longevity & Regeneration

24. Sonntag, W. E., et al. IGF-1 deficits and aging. J Gerontology A: Biological Sciences, 60(5), 536–547 (2005).

25. Breese, C. R., et al. IGF-1 signaling in sarcopenia and mitochondrial aging. Aging Cell, 10(5), 852–860 (2011).

26. Campisi, J., et al. IGF-1 signaling and cellular senescence. Nature Reviews Molecular Cell Biology, 10(9), 655–665 (2009).

Clinical & Translational Research

27. Kemp, S. F., et al. IGF-1 therapy in GH-resistant patients. Hormone Research, 64(3), 116–123 (2005).

28. Walenkamp, M. J., et al. IGF-1 receptor mutations and implications for analog therapy. Hormone Research, 71(Suppl 2), 65–71 (2009).

29. Berryman, D. E., et al. IGF-1 in human performance and tissue repair. Sports Medicine, 43(8), 609–623 (2013).

IGF-1 LR3 (Long Arg3 Insulin-Like Growth Factor-1)